Log in
NASDAQ:BTAI

BioXcel Therapeutics Stock Forecast, Price & News

$42.05
-2.22 (-5.01 %)
(As of 09/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$41.91
Now: $42.05
$44.55
50-Day Range
$37.44
MA: $43.12
$48.61
52-Week Range
$3.76
Now: $42.05
$71.50
Volume475,203 shs
Average Volume614,314 shs
Market Capitalization$940.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Read More
BioXcel Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BTAI
CUSIPN/A
Phone475-238-6837

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.49 per share

Profitability

Net Income$-32,970,000.00

Miscellaneous

Employees18
Market Cap$940.03 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$42.05
-2.22 (-5.01 %)
(As of 09/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BTAI News and Ratings via Email

Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

How has BioXcel Therapeutics' stock price been impacted by COVID-19?

BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BTAI shares have increased by 42.6% and is now trading at $42.05.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of BioXcel Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioXcel Therapeutics
.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for BioXcel Therapeutics
.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics Inc (NASDAQ:BTAI) posted its quarterly earnings data on Friday, August, 14th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.32.
View BioXcel Therapeutics' earnings history
.

What price target have analysts set for BTAI?

7 brokers have issued 12-month target prices for BioXcel Therapeutics' shares. Their forecasts range from $24.00 to $175.00. On average, they anticipate BioXcel Therapeutics' stock price to reach $95.57 in the next twelve months. This suggests a possible upside of 127.3% from the stock's current price.
View analysts' price targets for BioXcel Therapeutics
.

Who are some of BioXcel Therapeutics' key competitors?

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Crispr Therapeutics (CRSP), JD.Com (JD), Inseego (INSG), Tesla (TSLA), Marvell Technology Group (MRVL), Editas Medicine (EDIT), InVitae (NVTA) and Square (SQ).

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the following people:
  • Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 58)
  • Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 63)
  • Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 50)
  • Mr. Richard I. Steinhart MBA, Chief Financial Officer (Age 62)
  • Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 47)

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.85%), Avidity Partners Management LP (1.92%), Logos Global Management LP (1.48%), Driehaus Capital Management LLC (1.40%), FMR LLC (0.75%) and Nuveen Asset Management LLC (0.69%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta.
View institutional ownership trends for BioXcel Therapeutics
.

Which major investors are selling BioXcel Therapeutics stock?

BTAI stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, California Public Employees Retirement System, Moody Aldrich Partners LLC, EAM Investors LLC, Federated Hermes Inc., Driehaus Capital Management LLC, Russell Investments Group Ltd., and AQR Capital Management LLC.
View insider buying and selling activity for BioXcel Therapeutics
.

Which major investors are buying BioXcel Therapeutics stock?

BTAI stock was purchased by a variety of institutional investors in the last quarter, including Logos Global Management LP, Avidity Partners Management LP, Canada Pension Plan Investment Board, Opaleye Management Inc., Vanguard Group Inc., Goldman Sachs Group Inc., Bank of America Corp DE, and Alps Advisors Inc.. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart, and Vimal Mehta.
View insider buying and selling activity for BioXcel Therapeutics
.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $42.05.

How big of a company is BioXcel Therapeutics?

BioXcel Therapeutics has a market capitalization of $940.03 million. The company earns $-32,970,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. BioXcel Therapeutics employs 18 workers across the globe.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.